Every 10-Q that Treace Medical Concepts, Inc. (TMCI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TMCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMCI filings page.
Treace Medical Concepts (TMCI) reported Q3 2025 results. Revenue was $50.2 million, up 11.4% year over year, as more bunion procedure kits were sold, partly offset by lower average selling prices on newer systems. Gross profit was $39.7 million. Operating expenses were $55.4 million, leading to a net loss of $16.3 million, or $0.26 per share.
For the first nine months of 2025, revenue reached $150.2 million and net loss was $49.6 million, or $0.79 per share. As of September 30, 2025, cash and cash equivalents were $7.7 million and marketable securities were $49.7 million. Total principal outstanding under the term and revolving loans was $54.0 million. Stockholders’ equity was $89.2 million. Shares outstanding were 63,718,073 as of October 31, 2025.
Management noted continued adoption of minimally invasive osteotomy solutions and competitive pressures, which have reduced average selling prices even as kit volumes increased.